Clarifying the Link Between the Blood Lactate Concentration and Cardiovascular Risk

Authors
Christoph Ahlgrim¹, ², ³, Manfred W. Baumstark², ⁴, Kai Roecker⁵, ², ⁶

Affiliations
1 University Heart Center Freiburg, Medical Center-University of Freiburg, Bad Krozingen, Germany
2 Institute for Exercise- and Occupational Medicine, Medical Center-University of Freiburg, Freiburg, Germany
3 University of Freiburg Faculty of Medicine, Freiburg, Germany
4 University of Freiburg Faculty of Medicine, Freiburg, Germany
5 Applied Public Health, Furtwangen University of Applied Sciences, Furtwangen, Germany
6 University of Freiburg Faculty of Medicine, Freiburg, Germany

Key words
lactate, cardiovascular risk, blood lipids, glycolysis

accepted 28.03.2022
published online 2022

Bibliography
Int J Sports Med
DOI 10.1055/a-1812-5840
ISSN 0172-4622
© 2022. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Correspondence
Dr. Christoph Ahlgrim
Medical Center-University of Freiburg
Cardiology II
Südring 15
79189 Bad Krozingen
Germany
Tel.: + 4976334020
Christoph.Ahlgrim@uniklinik-freiburg.de

ABSTRACT
The blood lactate value at rest (Lacrest) is linked to cardiovascular outcomes. It is unclear whether this association holds true in younger, healthy subjects, especially as the pathophysiological connection between Lacrest and cardiometabolic disease is not well understood. The aim of this study is clarifying the link between Lacrest and cardiovascular risk, and to study explanatory factors for the variance of Lacrest concerning metabolism and physical activity in a population of healthy patient-athletes. The distribution and intra-individual variability of Lacrest was assessed based on 9051 samples. The 10-year cardiovascular risk was then approximated using the Framingham risk score in a group of 1315 samples from patient-athletes. Cross-validated linear regression was used to analyze explanatory variables for Lacrest and 10-year cardiovascular risk. Lacrest is weakly associated with the Framingham score. This association disappears when adjusting for blood lipids. Lacrest is also linked to the predominant type of exercise with endurance athletes featuring a higher Lacrest. Lacrest does not independently predict the estimated cardiovascular risk but is associated with lipid parameters. Moreover, the intra-individual variability of Lacrest is high in a relevant number of subjects, which does not point towards the feasibility to use Lacrest as an individual risk factor.

Introduction
Both exercise physiologists and clinicians have studied lactate metabolism for decades. Once assumed to be simply a byproduct of anaerobic energy metabolism, which might act as a substrate when conditions are aerobic, lactate actually is a signaling molecule with relation to metabolic regulation [1].

Clinically, blood lactate levels have been interpreted to point towards insufficient oxygen delivery (e. g., in sepsis or cardiac or bowel ischemia) [2–4] to tissues and other pathologies [5]. Moreover, blood lactate levels at rest (Lacrest) and during exercise are also used as a marker of primary mitochondrial dysfunction and
hence, lack of oxidative capacity of the cells, due to hereditary enzyme defects [6] or even deconditioning [7].

Recent work based on data gathered during the Atherosclerosis Risk in Communities (ARIC) study has demonstrated an association between Lactate (Lac) rest and cardiovascular outcomes [8], development of diabetes mellitus [9, 10], hypertension [11] and carotid atherosclerosis [12], which points towards a clinical significance of this parameter, possibly through its link to general energy metabolism.

As unfavorable metabolic changes manifesting at a young age might already impact on long-term cardiovascular risk [13], the aim of this article, therefore, is to investigate the relationship between Lac rest and cardiovascular risk with respect to blood lipids, physical fitness and in a relatively young study group of healthy patient-athletes.

Knowledge about both, the distribution of Lac rest in a healthy population and its intra-individual variation in repeated measurements is an indispensable prerequisite to assess whether Lac rest is suitable to point towards an increased cardiovascular risk on an individual level. To our knowledge, there is a scarcity of data concerning these parameters. Therefore, and as a preliminary step for the key study aim, the distribution of the Lac rest and the relation between inter- and intra-individual variation will be studied based on a large dataset of healthy patient-athletes.

Materials and Methods

The local hospitals ethics committee has approved the study. In a retrospective analysis of our database, 9051 datasets of 5575 individual patients ("patient-athletes", for subject characteristics, see Table 1) who visited our outpatient department in between 2007 and 2016 for lactate-based performance testing were identified that qualified to be further studied. The term "patient-athlete" is used because the subjects were either competitive or leisure-time athletes (from strength/speed or mainly endurance determined type of sports) or were performing the lactate-based performance test to establish regular physical activity (sedentary group). The subjects were allocated to their predominant type of physical adaptation by their self-reported primary sport during at least one year before the examination. This assignment was taken from the criteria in Olympic sports medicine [14]. These datasets were used to describe the distribution of Lac rest.

For a subgroup of 836 of these subjects, replicate measurements of Lac rest were available. This subgroup was analyzed to determine intra- to inter-individual variation of Lac rest (see below).

The key study sample consists of the 1315 subjects for whom Lac rest as well as clinical chemistry data, anthropometric data and results from an exercise stress test are available. For these subjects, 10-year cardiovascular risk was calculated using the Framingham score [15]. Subjects with a Lac rest outside the normal range for Lac rest as described below were not excluded from the analysis.

Lactate analysis and clinical chemistry

For lactate analysis, samples were taken at rest before routine ergometer testing using capillary sampling from the hyperemized earlobe. Resting conditions were uncontrolled but performing the resting ECG and echocardiography before the ergometer procedure allowed for a resting period of at least 30 minutes before capillary sampling. During this period, the blood pressure was determined in a supine position using the Riva-Rocci method on the left arm. Lactate was measured from these hemolyzed whole-blood samples on either Eppendorf EBIOS plus (Wesseling-Berzdorf, Germany) or EKF Biosen analyzers (Barleben, Germany) within a maximum period of up to one hour after withdrawal enzymatic-amperometrically. We calibrated the analyzers before each measurement cycle; hence, the impact of ambient temperature variation in the laboratory is negligible. All lactate analyzers used in our laboratory undergo interlaboratory comparison as requested by German authorities for hospital laboratory analysis (RiLi-BÄK). All other laboratory parameters were obtained from venous blood samples taken before exercise stress testing from an antecubital vein and were either analyzed in our own (full blood count, HDL, LDL) or our hospital’s central laboratory (total cholesterol, triglycerides, glucose) by conventional methods. Not all measures were determined in all subjects (see Table 1).

Performance testing

All subjects underwent a graded exercise test on either a bicycle ergometer or a treadmill until subjective exhaustion. was estimated from maximal performance using the ACSM equations. [16].

Statistics

All statistical analyses were performed using R [17]. Reference values for Lac rest were determined using parametric descriptive statistics. To determine whether individual reference ranges for Lac rest are applicable and to obtain a reference to determine effect size, intra- versus inter-subject variability of the respective measures was expressed as ratio r, which was introduced by Eugene Harris [18]. Variance analysis for calculation of r was performed using a linear mixed-effects model fitted by maximum likelihood ("nlme" package, [19]) on a subset of 836 subjects for whom multiple measurements were available for analysis; we analyzed all available replicates.

The Framingham risk score as an estimator of cardiovascular risk [15, 20] was calculated from all available data using the "framinghamriskequation" R package [21] using the "CVD" preset. The Framingham risk score estimates the 10-year-risk for the occurrence of a cardiovascular event (coronary artery disease, stroke, congestive heart failure and peripheral vascular disease) from input variables such as sex and age as well as the lipoprotein profile, the systolic blood pressure, and the smoker status and presence of diabetes. The parameter "left ventricular hypertrophy in ECG" was omitted in calculating cardiovascular risk because left ventricular hypertrophy in our cohort was most probably a benign adaptation to training.

A correlation analysis was used to display the raw association between Lac rest and the estimated cardiovascular risk. Cohen’s definition of effect size for correlation coefficients [22] was used to describe the effect size of observed correlation coefficient. To account factors confounding the association between Lac rest and the cardiovascular risk, and to investigate the association between Lac rest and other established predictors of cardiovascular risk, linear regression modelling was used. Because of the large sample size, a k-fold cross validation method (with k = 10) could be used for all linear modelling and correlation analyses [23]. We performed all analy-
The mean lactate value at rest was $1.16 \pm 0.29 \text{ mmol} \cdot \text{l}^{-1}$. Based on these values of an apparently healthy group of subjects, the normal range for resting lactate concentration, expressed as mean ± 2 SD, spans from 0.58 to 1.74 mmol \cdot l^{-1}. 3.3% of all lactate values observed at rest were higher than this observed upper limit of normal in our cohort.

Analysis of intra- to interindividual variation of Lac_{rest} yielded an r value of 3. The intra-individual standard deviation was 0.75 mmol \cdot l^{-1}, the interindividual standard deviation was 0.25 mmol \cdot l^{-1}.

### Association between Lac_{rest} and 10-year cardiovascular risk

For this analysis data from 1315 samples (414 female) with a mean age of 37.2 ± 17.2 was analyzed (for further details see ▶ Table 1b). Of these, 704 samples were from "endurance" adapted athletes (thereby were 312 leisure time athletes predominantly performing endurance exercise, 140 track and field athletes, 83 triathletes, 34 Nordic skiers, and 30 from other endurance disciplines), 329 were from "strength/speed" athletes (142 from leisure time athletes predominantly performing strength training, 80 from soccer players, 19 from alpine skiers, 16 from handball players, 15 from track and field athletes from sprint and throwing disciplines, 14 from wrestlers, 11 from tennis players and 32 from other non-endurance disciplines) and 282 form those subjects classified as "sedentary" or sports beginners.

The association between the estimated cardiovascular risk and Lac_{rest} is illustrated in ▶ Fig. 1a. Correlation analysis yielded a "low" correlational effect (Spearman’s rho = 0.20, p < 0.001) between Lac_{rest} and the estimated cardiovascular risk. Analyses of the association between the estimated cardiovascular risk and Lac_{rest} within the subgroups with respect to the different types of predominant training adaptation are displayed in ▶ Fig. 1b–d.

The results of the regression analysis investigating the contribution of Lac_{rest} to predicting cardiovascular risk with established risk markers are presented in ▶ Table 2. In this linear regression model Lac_{rest} is not a significant predictor of the estimated 10-year cardiovascular risk in our study sample. The association between Lac_{rest} and metabolic parameters determining cardiovascular risk and measures of physical activity, respectively, are illustrated in ▶ Tables 3 and 4. Lac_{rest} is statistically associated with sex, serum glucose, triglycerides, and HDL-cholesterol but not LDL-cholesterol. Moreover, Lac_{rest} is associated with the predominant type of exercise that is conducted by the subject but not aerobic performance per se. Both models feature a "small" effect size of the predictors for explaining Lac_{rest}.

### Results

#### Descriptive statistics and intra- to interindividual variation of Lac_{rest}

The descriptive statistics for the characteristics of the subjects (n = 9051 samples; 6087 taken from male and 2964 taken from female subjects, mean age 24.6 ± 14.7 years) for each sample taken for this analysis is displayed in ▶ Table 1a.

<table>
<thead>
<tr>
<th>Table 1a</th>
<th>Subject characteristics for samples to create reference range (n = 9051).</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Sex</td>
<td>6087 male/2964 female</td>
</tr>
<tr>
<td>Age (yrs.)</td>
<td>24.6 ± 14.7</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.1 ± 3.8</td>
</tr>
<tr>
<td>Exercise type (“Endurance”/“Strength/Speed”/“Sedentary”)</td>
<td>4670/3624/757</td>
</tr>
<tr>
<td>VO2peak (ml/min/kg)</td>
<td>49.6 ± 10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 1b</th>
<th>Subject characteristics of study sample (n=1315).</th>
</tr>
</thead>
<tbody>
<tr>
<td>b. Sex</td>
<td>901 male/414 female</td>
</tr>
<tr>
<td>Age (yrs.)</td>
<td>37.2 ± 17.2</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.9 ± 3.9</td>
</tr>
<tr>
<td>Predominant type of exercise (“Endurance”/“Strength/Speed”/“Sedentary”)</td>
<td>704/329/282</td>
</tr>
<tr>
<td>VO2peak (ml/min/kg)</td>
<td>43.5 ± 11</td>
</tr>
<tr>
<td>Estimated 10-year cardiovascular risk</td>
<td>0.035 ± 0.05 (median 0.015)</td>
</tr>
<tr>
<td>HDL-cholesterol (mg/dl)</td>
<td>59.0 ± 14.7</td>
</tr>
<tr>
<td>LDL-cholesterol (mg/dl)</td>
<td>127.4 ± 36.4</td>
</tr>
<tr>
<td>Serum glucose (mg/dl)</td>
<td>87.1 ± 16.4</td>
</tr>
<tr>
<td>Serum triglycerides (mg/dl)</td>
<td>108.6 ± 71.5</td>
</tr>
<tr>
<td>Lac_{rest} (mmol/ml)</td>
<td>1.17 ± 0.31</td>
</tr>
</tbody>
</table>

BMI: body-mass-index, Lac_{rest}: Lactate at resting conditions.

### Discussion

#### Lac_{rest} and cardiovascular risk

Recent analyses using a population-based approach are linking atherosclerotic disease with Lac_{rest}: Publications based on the ARIC study have highlighted a link between Lac_{rest} with mortality [8], atherosclerosis [9, 12] and metabolic disease [10]. It was speculated whether this was due to Lac_{rest} pointing towards an "insufficient oxidative capacity" [8].

Our data, based on a young and very fit study group featuring a low cardiovascular risk (median: 1.5%), also confirms an association between Lac_{rest} and 10-year cardiovascular risk, when Lac_{rest} is used as a single predictor, which is consistent within subgroups of the respective predominant type of exercise (see ▶ Fig. 1a–d). However, when parameters of the lipid profile and other known risk modifiers are included in the prediction model, Lac_{rest} does not appear as an independent predictor of cardiovascular risk in our population. This is most probably because in our cohort, a significant association was observed between Lac_{rest} and metabolic factors such as serum glucose, serum triglycerides, and HDL-cholesterol but not LDL-cholesterol (see ▶ Table 3). Whilst the present cohort is younger and healthier than the subjects of the ARIC trials, the general finding of an association between Lac_{rest} and the lipoprotein profile was also observed in subjects of the ARIC trial (e. g. [8]). However, the main difference between our study and the reports from the ARIC trial is that in our cohort, Lac_{rest} loses its predictive
value for cardiovascular risk when adjusted for confounders, whereas the reports from the ARIC trial yielded significant associations even when fully adjusting for the lipoprotein profile.

Our data illustrates that when studying an association between Lac-rest and cardiovascular risk and/or metabolic disease, these associations need to be accounted for not to attribute direct predictive properties to a possibly “bystanding” molecule in the cardiovascular risk profile. The observation of a remarkable intra-individual variability (see below) further supports this notion pointing towards a rather second-tier role of Lac-rest in our cohort when aiming to gain insights concerning cardiovascular risk. In this context, it is important that our healthy study group did not feature relevant cardiovascular disease or diabetes as opposed to the subjects of the ARIC trial.

Interestingly, and without further specification, higher Lac-rest values were interpreted as pointing towards impaired oxidative capacity by other researchers speculating on the mechanism by which Lac-rest might impact on cardiometabolic disease [10]. Of note, Mat-

![Fig. 1](image)

**Table 2** Results of linear regression analysis (k-fold validation, k = 10) for explanatory parameters for cardiovascular risk.

<table>
<thead>
<tr>
<th></th>
<th>Estimate</th>
<th>Std. Error</th>
<th>t value</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>-12.7900</td>
<td>9.84600</td>
<td>-1.299</td>
<td>0.194187</td>
</tr>
<tr>
<td>Age (years)</td>
<td>2.0090</td>
<td>0.05537</td>
<td>36.288</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HDL-cholesterol (mg/dl)</td>
<td>-0.7782</td>
<td>0.06033</td>
<td>-12.900</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LDL-cholesterol (mg/dl)</td>
<td>0.1928</td>
<td>0.02344</td>
<td>8.226</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Sex = female</td>
<td>-12.7700</td>
<td>2.01300</td>
<td>-6.344</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Serum triglycerides (mg/dl)</td>
<td>0.0505</td>
<td>0.01142</td>
<td>4.421</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>VO2max (ml/min/kg)</td>
<td>-0.3851</td>
<td>0.10130</td>
<td>-3.801</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Serum glucose (mg/dl)</td>
<td>0.1677</td>
<td>0.04655</td>
<td>3.603</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Predominant exercise = &quot;Strength/Speed&quot;</td>
<td>5.7890</td>
<td>2.00300</td>
<td>2.891</td>
<td>0.0039</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>-0.2212</td>
<td>0.14410</td>
<td>-1.535</td>
<td>0.1250</td>
</tr>
<tr>
<td>Predominant exercise = &quot;Sedentary&quot;</td>
<td>-3.3200</td>
<td>2.45900</td>
<td>-1.350</td>
<td>0.1771</td>
</tr>
<tr>
<td>Lac-rest (mmol/l)</td>
<td>-0.4694</td>
<td>2.49400</td>
<td>-0.188</td>
<td>0.8507</td>
</tr>
</tbody>
</table>

R² for final model = 0.7090968. RMSE of cross-validation: 0.0268284. f² = 2.44

Cardiovascular risk: 10-year-cardiovascular-risk estimated by the Framingham score. BMI: body-mass-index, Lac-rest: Lactate at resting conditions.
In the so-called “indirect pathway” [26, 27]. Lac rest is also physiologically linked to the diurnal blood glucose and insulin levels [28]. However, this relation is affected by metabolic disease which might lead to a higher basal lactate production of adipocytes but also deteriorate the capacity of adipocytes to provide lactate in response to glucose ingestion as part of this “indirect pathway” [29].

Physiologically, Lacrest Values are not necessarily related to oxidative capacity: A relevant proportion of glucose coming from the digestive tract bypasses the liver and is consequently metabolized in peripheral tissues leading to glycolysis and lactate production [26, 27]. The lactate then enters the liver through the bloodstream in the so-called “indirect pathway” [26, 27]. Lacrest is also physiologically linked to the diurnal blood glucose and insulin levels [28]. However, this relation is affected by metabolic disease which might lead to a higher basal lactate production of adipocytes but also deteriorate the capacity of adipocytes to provide lactate in response to glucose ingestion as part of this “indirect pathway” [29].

This regulation of Lacrest appears to be independent from a so called “oxidative capacity” of muscle tissue and might explain the associations between the relation between Lacrest and cardiometabolic disease that were observed in the ARIC trial.

Possibly, the systematically higher Lacrest levels that we observe in subjects who predominantly conducted endurance training (and most probably therefore feature an excellent oxidative capacity) in our study sample will not have the same physiological basis as the elevation of Lacrest observed in the subjects from the ARIC study featuring increased cardiovascular risk and cardiometabolic disease. In those subjects the observation of an association between Lacrest and cardiometabolic disease might be explained by regarding Lacrest rather as a symptom of an already-manifest, subclinical cardiometabolic condition.

Distribution of Lacrest

To our knowledge, this study is the first to establish normal values for Lacrest in capillary blood based on a larger population of young healthy adults. When comparing the upper limit of normal based on our data, which is 1.74 mmol·l⁻¹, this appears to be slightly lower than the arbitrary threshold of 2.0 mmol·l⁻¹ that is commonly used in clinical practice [30]. Noteworthy, our study sample yielded an effect of sex on Lacrest with female sex being associated with lower lactate values. When comparing the Lacrest Values of our cohort with data available from the ARIC publications, most study groups featured lactate values that are compatible with our reference range ([10]: high risk group 1.21–1.63 mmol/l; [9]: considered normal range 0.5–2.2 mmol/l), but some authors observed Lacrest values well above our level of normal ([8], highest included Lacrest 55.5 mg/dl = 6.16 mmol/l). From a methodological point of view, it is relevant that lactate in the ARIC trial was measured from

<table>
<thead>
<tr>
<th>Estimate</th>
<th>Std. Error</th>
<th>t value</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>1.3063134</td>
<td>0.0492455</td>
<td>26.527</td>
</tr>
<tr>
<td>sex = female</td>
<td>−0.1150247</td>
<td>0.0192080</td>
<td>−5.988</td>
</tr>
<tr>
<td>Predominant exercise = “Strength/Speed”</td>
<td>−0.0839597</td>
<td>0.0210391</td>
<td>−3.991</td>
</tr>
<tr>
<td>Predominant exercise = “Sedentary”</td>
<td>−0.0763436</td>
<td>0.0257877</td>
<td>−2.960</td>
</tr>
<tr>
<td>VO2peak (ml/min/kg)</td>
<td>−0.0014581</td>
<td>0.0009672</td>
<td>−1.508</td>
</tr>
</tbody>
</table>

R² for final model = 0.04858364. RMSE of cross-validation: 0.2993456. f² = 0.05

sushita and colleagues report a “sports score” which is towards less physical activity in subjects with higher lactate values [8].

The data obtained from our healthy study population do not conform this link between a reduced oxidative capacity and Lacrest. First, Lacrest is not significantly associated with the maximum oxygen uptake estimated from stress testing, which per definition, is the maximal oxidative capacity of the body during exercise (see Table 4).

Second, our analyses show an association (of “small” effect size) between Lacrest and the predominant type of exercise adaptation in our study sample (see Table 4), that is somewhat contrastive to the concept “increased Lacrest – reduced oxidative capacity”: while subjects, who conduct predominantly endurance-type exercise showed slightly higher Lacrest values, subjects conducting mostly “strength/speed”-type of exercise appear to have lower Lacrest values. Sedentary subjects feature Lacrest that are somewhere in between the two physically active groups. This points towards other mechanisms of elevated lactate values than a reduced oxidative capacity, as especially endurance athletes would be expected to feature muscle tissue with a higher oxidative capacity [25].
plasma [8, 11, 31] and not from whole blood as in our study. The
difference between our observations and those made from the
ARIC study with respect to the association between cardiovascular
risk or disease and Lacrest do most probably not arise from system-
aric differences of Lacrest levels between our study groups.

However, a reference range for Lacrest solely describes between-
subject variation. When developing and interpreting reference
ranges for a laboratory parameter, the inter- as well as the intra-indi-
vidual variation must be taken into account [18]. When the intra-
individual variability is much lower than the inter-individual varia-
tion of a parameter, population-based reference values might not
detect all relevant alterations on the individual level.

Our analysis bases on r, the ratio between the intra- and inter-
individual variations, which was proposed by Eugene Harris (1974).
When r is small (< 0.6, “marked individuality”), the intra-individu-
distribution of measurements is smaller than the overall variance
of samples taken from a population. Laboratory parameters with
such a small r are suitable for clinical decision making based on
individual threshold levels. We observed an r value of 3 in repeated
measurements of Lacrest in the same subjects.

For r values ≥ 1.4, the conventional limits include both, meas-
urements of subjects whose intra-individual variations are smaller
than average, but also those whose variation values are larger than
average [18]. This further illustrates that a Lacrest value within the
normal range appears not to be suitable to be included into risk
prediction algorithms for the individual “chronic” cardiovascular
risk as it does not feature sufficient reliability for all subjects. In
this context, it is important to emphasize that the parameter estimates
of the associations between Lacrest and predictive variables (with a
small but significant effect size) such as sex, lipid parameters, and
exercise type are lower than the inter- and intra-individual variation
of Lacrest observed in our study sample. Although this may indicate
a possible physiological background, the clinical relevance of these
observations appears to be dubious. It can be speculated that fu-
ture investigations aiming to confirm a link between Lacrest and the
statistically associated parameters can be improved by vigorously
standardizing the carbohydrate intake in the period before the analy-
sis because Lacrest is closely linked to blood glucose and serum ins-
ulin levels [29].

Limitations

Per design, this study is unable to establish cause-and-effect rela-
tionships. Bias might be introduced by the choice of cardiovascu-
lar risk calculation: whilst the Framingham risk score was recom-
med by the European Society of Cardiology’s Guideline at the
time of data acquisition [32], it was recently shown that Framing-
ham risk models might overestimate cardiovascular risk in non-US
cohorts and subjects at higher risk [33]. Moreover, to our knowl-
dge, the Framingham risk score has not been validated in an ath-
etic population, which on the other hand side holds true for all al-
gorithms for cardiovascular risk prediction. In this context, it is
noteworthy that “presence of left ventricular hypertrophy in ECG”
was omitted for the calculation of cardiovascular risk, because in
this cohort, left ventricular hypertrophy most probably constitutes
a benign adaptation to training. However, this might lead to a sys-
tematic bias in calculation of the risk model. The population of the
present study is on average younger and most probably, much fit-
ter and healthier than the subjects participating in the ARIC stud-
ies. Therefore, a direct comparison between the two study samples
might be affected by fitness, presence of disease and age, which
might hinder direct transferability of our results. As in all observa-
tional studies, although adjustments were performed using mul-
tiparameter models, we cannot exclude residual confounding.

Conclusion

Our study describes the distribution of blood lactate concentration
values at physical rest based on capillary blood samplings in healthy
subjects. The results of regression analyses points towards a rela-
tion between lactate values at rest with metabolic parameters and
the predominant type of exercise, whereas no self-contained pre-
dictive property is seen concerning the prediction of the estimated
10-year cardiovascular risk in a young-healthy group of patient-
athletes.

Contributor statement

(in accordance to ICMJE recommendations): CA, MW, KR: concep-
tion and design, analysis and interpretation of data, drafting and
revising the manuscript.

Funding

This study was conducted based on funding by the investigator
sites. No external funding was provided for conduction of this
study.

Conflict of Interest

The authors declares that they have no conflict of interest.

References

Metab 2018; 27: 757–785. doi:10.1016/j.cmet.2018.03.008

lactate level predict the extent of bowel ischemia in patients
presenting to the emergency department with acute mesenteric
doi:10.1155/2017/8038796

doi:10.21037/jtd.2016.05.55

arterial lactate levels in patients with ST-segment elevation myocardial
doi:10.1186/cc9253

88: 1127–1140. doi:10.1016/j.mayocp.2013.06.012

Wochenschr 1997; 109: 93–99